Increasing Prevalence of Chronic Diseases to Augment the Central Nervous System Biomarkers Market Growth
There are many things that can be used to determine the
existence of a person's central nervous system. This includes a wide array of
medical conditions that can exhibit symptoms such as headaches, migraines,
heart palpitations, sweating, back aches, neck pain, numbness, and even more
serious conditions such as cardiovascular disease. However, not all of these
conditions can produce accurate test results. To this end, there are other
tests that can be performed to diagnose someone with central nervous system abnormality.
Central nervous system biomarkers are quantifiable and
measurable biological indicators that can be used to diagnose or predict
disease, monitor disease progression, and predict treatment response.
Biomarkers help understand the development of chronic diseases and identify
subjects who are at high risk of developing disease.
Market Dynamics:
Increasing prevalence of chronic diseases, such as
Alzheimer’s, is expected to propel the growth of the central
nervous system biomarkers market. Alzheimer's disease is the most common
form of dementia and may contribute to 60 to 70% of cases. According to the
World Health Organization (WHO), around 50 million people worldwide have
dementia and there are nearly 10 million new cases every year.
Increasing number of pipeline studies by key players for the
development of biomarkers is expected to fuel the growth of the central nervous
system biomarkers market. For instance, in Jan 2021, Aptinyx Inc. announced the
publication of a recent review article in Medicine in Drug Discovery featuring
data on its novel NMDA receptor modulator, NYX-2925. Moreover, the company has
three product candidates in clinical development in central nervous system
indications, including chronic pain, post-traumatic stress disorder, and
cognitive impairment associated with Parkinson’s disease.
The emergence of COVID-19 is expected to offer lucrative
growth opportunities for players in the central nervous system biomarkers
market. For instance, in Jan. 2021, Mitsubishi Tanabe Pharma America announced
revisions to the REFINE-ALS biomarker study protocol to address the safety of
people with amyotrophic lateral sclerosis (ALS) during the pandemic.
Competitive Analysis:
Major players operating in the central nervous system
biomarkers market are Merc & Co., Applied Neurosolutions, Exonhit
Therapeutics, Avacta Group, Avid Radiopharmaceuticals Inc., Banyan Biomarkers,
Diagenic ASA, Aposense, Alseres Pharmaceuticals Inc., Apitope International,
Adlyfe Inc., Acumen Pharmaceuticals Inc., Abastar MDX Inc., EKF Diagnostics
Holdings Inc., Abiant Inc., Enzo Biochem Inc., and Thermo fisher scientific.
In January 2021, Ultragenyx Pharmaceutical announced that
the United States Food and Drug Administration (FDA) has cleared the
Investigational New Drug application for UX701, an investigational AAV9 gene
therapy being evaluated for the treatment of Wilson Disease.
Comments
Post a Comment